FBXW7 and ovarian cancer: Five RCTs reported the results of patients with newly diagnosed ovarian cancer (anti-angiogenesis group = 3,448; placebo group = 2649; total = 6097 patients): ICON7, GOG-0218, AGO-OVAR16, AGO-OVAR 12, TRINOVA-3 (Ray-Coquard et al., 2020; Vergote et al., 2019a; Vergote et al., 2019b; du Bois et al., 2014; Tewari et al., 2019; Burger et al., 2011; Oza et al., 2015).